Company Name: |
TargetMol Chemicals Inc.
|
Tel: |
15002134094 |
Email: |
marketing@targetmol.cn |
Products Intro: |
Product Name:S-309309 CAS:2267352-04-3 Package:50mg;10mg
|
|
| S-309309 Basic information |
Product Name: | S-309309 | Synonyms: | S-309309;Acetamide, N-[(4R)-5,7-difluoro-2,2′,3,4′,5′,7′-hexahydro-2′-(5-methyl-2-pyridinyl)-4′-oxospiro[4H-1-benzopyran-4,6′-[6H]pyrazolo[4,3-c]pyridin]-3′-yl]-2-(methylsulfonyl)- | CAS: | 2267352-04-3 | MF: | C23H21F2N5O5S | MW: | 517.51 | EINECS: | | Product Categories: | | Mol File: | 2267352-04-3.mol |  |
| S-309309 Chemical Properties |
Boiling point | 876.172±65.00 °C(Press: 760.00 Torr)(predicted) | density | 1.616±0.14 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | pka | 10.475±0.20(predicted) |
| S-309309 Usage And Synthesis |
Uses | S-309309 is an orally active and selective MGAT2 inhibitor. S-309309 can be used in metabolism-related research[1]. | in vivo | S-309309 (3 mg/kg, p.o., b.i.d., 6-13 weeks) inhibits food intake and body weight gain in DIO mice[1].
Animal Model: | High fat diet (HFD)-induced obesity (DIO) mice[1] | Dosage: | 3 mg/kg | Administration: | p.o., b.i.d., 6-13 weeks | Result: | Decreased in insulin resistance index, hepatic triglycerides content, plasma alanine aminotransferase and aspartate aminotransferase level, and gene expression related to fibrosis.
Enhanced energy expenditure and upregulation of intestinal gene expression related to long-chain fatty acid beta oxidation.
|
| IC 50 | MGAT2 | References | [1] Miyano T, et al. The Continuous and Reversible Transformation of the Polymorphs of an MGAT2 Inhibitor (S-309309) from the Anhydrate to the Hydrate in Response to Relative Humidity. Pharmaceutics. 2024 Jul 17;16(7):949. DOI:10.3390/pharmaceutics16070949 [2] YOSHIKI RYO, et al. 1649-P: S-309309, a Novel MGAT2 Inhibitor, Enhances Intestinal Fatty Acid Beta Oxidation and Provides Metabolic Benefits in DIO Mice. Diabetes, 2024, 73(Supplement_1). |
| S-309309 Preparation Products And Raw materials |
|